Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine最新文献

{"title":"The Impact of a Newly Established Multidisciplinary Team on the Interventional Treatment of Patients With Emphysema.","authors":"Vasileios Kouritas,&nbsp;Richard Milton,&nbsp;Emmanouel Kefaloyannis,&nbsp;Kostas Papagiannopoulos,&nbsp;Allesandro Brunelli,&nbsp;Doytchin Dimov,&nbsp;Sishik Karthik,&nbsp;Andrew Hardy,&nbsp;Peter Tcherveniakov,&nbsp;Nilanjan Chaudhuri","doi":"10.1177/1179548419852063","DOIUrl":"https://doi.org/10.1177/1179548419852063","url":null,"abstract":"<p><strong>Background: </strong>The emphysema interventional treatment involves mainly lung volume reduction surgery (LVRS) and endobronchial valve (EBV) implantation. Few institutes discuss these cases at a dedicated emphysema multidisciplinary team (MDT) meeting.</p><p><strong>Objectives: </strong>To investigate the impact of a newly established dedicated emphysema MDT meeting on the interventional treatment of such patients.</p><p><strong>Methods: </strong>During a study period of 4 years, the outcome of 44 patients who underwent intervention according to the proposal of the emphysema MDT (group A) was compared with the outcome of 44 propensity score matched patients (group B) treated without the emphysema MDT proposal.</p><p><strong>Results: </strong>More LVRS and less EBV insertions were performed in group A (<i>P </i>=<i> </i>.009). In group B, the interventions were performed sooner than in group A (<i>P </i>=<i> </i>.003). Postoperative overall morbidity and length of in-hospital stay were similar in the 2 groups (<i>P </i>=<i> </i>.918 and .758, respectively). Improvement of breathing ability was reported in more patients from group A (<i>P </i>=<i> </i>.012). In group B, the total number of re-interventions was higher (<i>P </i>=<i> </i>.001) and the time to re-intervention had the tendency to be less (<i>P </i>=<i> </i>.069). Survival was similar between the 2 groups (<i>P </i>=<i> </i>.884). Intervention without discussion at the MDT and EBV as initial intervention was an independent predictor of re-intervention.</p><p><strong>Conclusions: </strong>Interventional treatment for patients with chronic obstructive pulmonary disease (COPD) after discussion at a dedicated MDT involved more LVRS performed, required fewer interventions for their disease, and had longer re-intervention-free intervals and better breathing improvement.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"13 ","pages":"1179548419852063"},"PeriodicalIF":2.0,"publicationDate":"2019-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548419852063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37385320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Exploration Into Knowledge, Attitudes, and Beliefs Towards Risky Health Behaviours in a Paediatric Cystic Fibrosis Population.","authors":"Rebecca Keyte,&nbsp;Helen Egan,&nbsp;Michail Mantzios","doi":"10.1177/1179548419849427","DOIUrl":"10.1177/1179548419849427","url":null,"abstract":"<p><p>Risky behaviours are prevalent within the cystic fibrosis (CF) population; however, there is a lack of research which has investigated risky behaviour engagement among adolescents with CF, with reasons for initiation currently being unknown, as no qualitative studies have been conducted. This research therefore examines knowledge, attitudes, and beliefs towards risky behaviours at an age commonly associated with initiation. Ten paediatric participants were recruited. Thematic analysis illustrated several psychological factors associated with risky behaviours. A desire for normalcy was evident, with this been associated with a desire to engage in normalised risky behaviours. Evidence of a life-orientated illness perspective was also prevalent, with participants believing that many individuals engage in risky behaviours for fun. Overall, there was a reported lack of knowledge on consequences of risky behaviours, with many participants not being informed of these by health care professionals (HCPs). This research provides insight into an area of CF paediatric care which could be improved on, with the provision of awareness regarding risky behaviours not being embedded within paediatric CF care. Consequently, this research demonstrates the need for interventions to be integrated into paediatric CF care for the prevention and reduction of risky behaviours.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"13 ","pages":"1179548419849427"},"PeriodicalIF":2.0,"publicationDate":"2019-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548419849427","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37338553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory Fungal Diseases in Adult Patients With Cystic Fibrosis.","authors":"Emanuele Delfino,&nbsp;Filippo Del Puente,&nbsp;Federica Briano,&nbsp;Chiara Sepulcri,&nbsp;Daniele Roberto Giacobbe","doi":"10.1177/1179548419849939","DOIUrl":"https://doi.org/10.1177/1179548419849939","url":null,"abstract":"<p><p>Clinical manifestations of respiratory fungal diseases in adult cystic fibrosis (CF) patients are very heterogeneous, ranging from asymptomatic colonization to chronic infections, allergic disorders, or invasive diseases in immunosuppressed CF patients after lung transplantation. In this narrative review, mainly addressed to clinicians without expertise in CF who may nonetheless encounter adult CF patients presenting with acute and chronic respiratory syndromes, we briefly summarize the most representative clinical aspects of respiratory fungal diseases in adult CF patients.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"13 ","pages":"1179548419849939"},"PeriodicalIF":2.0,"publicationDate":"2019-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548419849939","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37339184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aztreonam Lysine Inhalation Solution in Cystic Fibrosis.","authors":"Elizabeth Claire Elson,&nbsp;Joel Mermis,&nbsp;Deepika Polineni,&nbsp;Christopher M Oermann","doi":"10.1177/1179548419842822","DOIUrl":"https://doi.org/10.1177/1179548419842822","url":null,"abstract":"<p><p>Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysregulated inflammation. Therapeutic innovations such as nebulized antimicrobial therapy targeting specific pathogens have resulted in improvements in quality of life and life expectancy. Aztreonam lysine for inhalation (AZLI) solution was initially approved to improve respiratory symptoms in CF patients with <i>Pseudomonas aeruginosa</i> (PA) in 2010 by the Food and Drug Administration. Since then, research broadening labeling and clinical application has been developed. In this review, we analyze published and ongoing research regarding AZLI therapy in CF. A search of the Cochrane Database of Systematic Reviews and the PubMed and ClinicalTrials.gov databases was conducted to identify publications about AZLI. Three pre-approval studies were identified and assessed. Two are Phase 3, placebo-controlled trials, assessing a variety of safety and efficacy endpoints, leading to FDA approval. The third is an open-label extension of the two previous trials. An additional seven post-approval, completed trials were identified and are included in this review. They represent a variety of study designs including safety and efficacy in patients with mild lung disease and young patients, an active comparator trial vs inhaled tobramycin, an eradication study, a study among patients with <i>Burkholderia cepacia</i>, and a study assessing continuous alternating antibiotic therapy. Finally, five ongoing clinical trials are discussed. Overall, studies demonstrated that inhaled aztreonam is a safe and effective antimicrobial treatment for the eradication of newly acquired <i>P. aeruginosa</i> and long-term suppressive therapy of chronic endobronchial infection among people with cystic fibrosis.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"13 ","pages":"1179548419842822"},"PeriodicalIF":2.0,"publicationDate":"2019-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548419842822","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37180429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystic Fibrosis Transmembrane Conductance Regulator Genotype, Not Circulating Catecholamines, Influences Cardiovascular Function in Patients with Cystic Fibrosis.","authors":"Alexander L Bisch,&nbsp;Courtney M Wheatley,&nbsp;Sarah E Baker,&nbsp;Elizabeth R Peitzman,&nbsp;Erik H Van Iterson,&nbsp;Theresa A Laguna,&nbsp;Wayne J Morgan,&nbsp;Eric M Snyder","doi":"10.1177/1179548419835788","DOIUrl":"https://doi.org/10.1177/1179548419835788","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems of the body and is characterized by mutation in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR). Previous work has shown that a single dose of aβ-agonist increases cardiac output (Q) and stroke volume (SV) and decreases systemic vascular resistance (SVR) in healthy subjects. This effect is attenuated in patients with CF; however, the mechanism is unknown. Potential explanations for this decreased cardiovascular response to a β-agonist in CF include inherent cardiovascular deficits secondary to the CFTR mutation, receptor desensitization from prolonged β-agonist use as part of clinical care, or inhibited drug delivery to the bloodstream due to mucus buildup in the lungs. This study sought to determine the effects of endogenous epinephrine (EPI) and norepinephrine (NE) on cardiovascular function in CF and to evaluate the relationship between cardiovascular function and CFTR F508del mutation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A total of 19 patients with CF and 31 healthy control subjects completed an assessment of Q (C&lt;sub&gt;2&lt;/sub&gt;H&lt;sub&gt;2&lt;/sub&gt; rebreathing), SV (calculated from Q and heart rate [HR]), Q and SV indexed to body surface area (BSA, QI, and SVI, respectively), SVR (through assessment of Q and mean arterial blood pressure [MAP]), and HR (from 12-lead electrocardiogram [ECG]) at rest along with plasma measures of EPI and NE. We compared subjects by variables of cardiovascular function relative to EPI and NE, and also based on genetic variants of the F508del mutation (homozygous deletion for F508del, heterozygous deletion for F508del, or no deletion of F508del).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Cystic fibrosis patients demonstrated significantly lower BSA (CF = 1.71 ± 0.05 m&lt;sup&gt;2&lt;/sup&gt; vs healthy = 1.84 ± 0.04 m&lt;sup&gt;2&lt;/sup&gt;, &lt;i&gt;P&lt;/i&gt; = .03) and SVI (CF = 30.6 ± 2.5 mL/beat/m&lt;sup&gt;2&lt;/sup&gt; vs healthy = 39.9 ± 2.5 mL/beat/m&lt;sup&gt;2&lt;/sup&gt;, &lt;i&gt;P&lt;/i&gt; = .02) when compared with healthy subjects. Cystic fibrosis patients also demonstrated lower Q (CF = 4.58 ± 0.36 L/min vs healthy = 5.71 ± 0.32 L/min, &lt;i&gt;P&lt;/i&gt; = .03) and SV (CF = 54 ± 5.5 mL/beat vs healthy = 73.3 ± 4.5 mL/beat, &lt;i&gt;P&lt;/i&gt; = .01), and a higher HR (CF = 93.2 ± 3.9 bpm vs healthy = 80.5 ± 2.7 bpm, &lt;i&gt;P&lt;/i&gt; &lt; .01) and SVR (CF = 2082 ± 156 dynes*s/cm&lt;sup&gt;-5&lt;/sup&gt; vs healthy = 1616 ± 74 dynes*s/cm&lt;sup&gt;-5&lt;/sup&gt;, &lt;i&gt;P&lt;/i&gt; = .01) compared with healthy subjects. Furthermore, CF patients demonstrated a lower SV (&lt;i&gt;P&lt;/i&gt; &lt; .01) corrected for NE when compared with healthy subjects. No significant differences were seen in HR or Q relative to NE, or SVR relative to EPI. Differences were seen in SV (F&lt;sub&gt;(2,14)&lt;/sub&gt; = 7.982, &lt;i&gt;P&lt;/i&gt; &lt; .01) and SV index (F&lt;sub&gt;(2,14)&lt;/sub&gt; = 2.913, &lt;i&gt;P&lt;/i&gt; = .08) when patients with CF were stratified according to F508del mutation (number of deletions).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Individuals with CF have lower cardiac an","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"13 ","pages":"1179548419835788"},"PeriodicalIF":2.0,"publicationDate":"2019-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548419835788","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37291239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone.","authors":"Anastasia Y Ipatova,&nbsp;Pamela H Koerner,&nbsp;Richard T Miller,&nbsp;Francis Staskon,&nbsp;Melanie Radi","doi":"10.1177/1179548419834922","DOIUrl":"https://doi.org/10.1177/1179548419834922","url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease which results in thickening and scarring of the interstitial tissue. As the only 2 Food and Drug Administration (FDA)-approved medications on the market, it is valuable to compare the impact of nintedanib and pirfenidone on clinical outcomes. Records of patients who started nintedanib or pirfenidone between calendar years 2015 and 2016 at a national specialty pharmacy were retrospectively reviewed. Data collection was derived from patient management applications and statistical data analysis was completed in SAS (SAS Institute Inc^®). The nintedanib population contained 2605 patients and of the population completing clinical assessment surveys (n = 1343), 46% of respondents (n = 612) reported no adverse events, with the remaining 54% reporting at least 1 adverse event. Average proportion of days covered (PDC) was 84.2% (SD = 17.0). Average final monthly copay for this group was $235. The pirfenidone population had 1322 patients, and of the surveyed population (n = 764), 58% of respondents (n = 445) reported no adverse events, with the remaining 42% reporting at least 1 adverse event. Average PDC was 83.4% (SD = 17.3). Average final monthly copay for this group was $339. Outcomes in the studied IPF population were similar for nintedanib and pirfenidone.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"13 ","pages":"1179548419834922"},"PeriodicalIF":2.0,"publicationDate":"2019-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548419834922","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37071812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Unusual Mass of Posterior Mediastinum: A Case of Retrotracheal Parathyroid Adenoma Presenting With Primary Hyperparathyroidism.","authors":"Sani Rabiou,&nbsp;Boubacar Efared,&nbsp;Sani Aminou,&nbsp;Hicham Harmouchi,&nbsp;Kassim Sidibé,&nbsp;Marouane Lakranbi,&nbsp;Yassine Ouadnouni,&nbsp;Mohamed Smahi","doi":"10.1177/1179548418811840","DOIUrl":"https://doi.org/10.1177/1179548418811840","url":null,"abstract":"<p><p>Although parathyroid ectopy in the mediastinum has been the subject of several publications, its location in the posterior mediastinum is very rarely reported. We report a case of a 69-year-old patient who presented with clinical symptoms of malignant hypercalcemia due to a retrotracheal mediastinal parathyroid adenoma. The surgical excision leads to a quick normalisation of the phosphocalcic balance with improvement of the clinical symptoms. Ectopic hypersecreting parathyroid adenoma with life-threatening hypercalcemia should prompt radiological assessment and appropriate surgical management to prevent further clinical complications.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"12 ","pages":"1179548418811840"},"PeriodicalIF":2.0,"publicationDate":"2018-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548418811840","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36719677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and Weaning from Mechanical Ventilation-An Exploratory Study.","authors":"Ogugua Ndili Obi,&nbsp;Mark Mazer,&nbsp;Charles Bangley,&nbsp;Zuheir Kassabo,&nbsp;Khalid Saadah,&nbsp;Wayne Trainor,&nbsp;Kenneth Stephens,&nbsp;Patricia L Rice,&nbsp;Robert Shaw","doi":"10.1177/1179548418801004","DOIUrl":"https://doi.org/10.1177/1179548418801004","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is associated with increased risk of hypercapnic respiratory failure, prolonged duration on mechanical ventilation, and extended weaning periods.</p><p><strong>Objective: </strong>Pilot study to determine whether morbidly obese adult tracheotomized subjects (body mass index [BMI] ⩾ 40) can be more efficiently weaned from the ventilator by optimizing their positive end-expiratory pressure (PEEP) using either an esophageal balloon or the best achieved static effective compliance.</p><p><strong>Methods: </strong>We randomly assigned 25 morbidly obese adult tracheotomized subjects (median [interquartile range] BMI 53.4 [26.4]; range 40.4-113.8) to 1 of 2 methods of setting PEEP; using either titration guided by esophageal balloon to overcome negative transpulmonary pressure (Ptp) (goal Ptp 0-5 cmH₂O) (ESO group) or titration to maximize static effective lung compliance (Cstat group). Our outcomes of interest were number of subjects weaned by day 30 and time to wean.</p><p><strong>Results: </strong>At day 30, there was no significant difference in percentage of subjects weaned. 8/13 subjects (62%) in the ESO Group were weaned vs. 9/12(75%) in the Cstat Group (<i>P</i> = 0.67). Among the 17 subjects who weaned, median time to ventilator liberation was significantly shorter in the ESO group: 3.5 days vs Cstat group 14 days (<i>P</i> = .01). Optimal PEEP in the ESO and Cstat groups was similar (ESO mean ± SD = 26.5 ± 5.7 cmH₂O and Cstat 24.2 ± 7 cmH₂O (<i>P</i> = .38).</p><p><strong>Conclusions: </strong>Optimization of PEEP using esophageal balloon to achieve positive transpulmonary pressure did not change the proportion of patients weaned. Among patients who weaned, use of the esophageal balloon resulted in faster liberation from mechanical ventilation. There were no adverse consequences of the high PEEP (mean 25.4; range 13-37 cmH₂O) used in our study. The study was approved by the Institutional Review Board at our institution (UMCIRB#10-0343) and registered with clinicaltrials.gov (NCT02323009).</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"12 ","pages":"1179548418801004"},"PeriodicalIF":2.0,"publicationDate":"2018-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548418801004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36518325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Exercise on Oxygen Content in Anemic Patients With Chronic Obstructive Pulmonary Disease.","authors":"Ahmet Sinan Copur,&nbsp;Hannan Dogar,&nbsp;Zhang Chao,&nbsp;Leandra Wallace,&nbsp;Kevin Henegar,&nbsp;Nashreen Anderson,&nbsp;Ashok Fulambarker","doi":"10.1177/1179548418796483","DOIUrl":"https://doi.org/10.1177/1179548418796483","url":null,"abstract":"<p><strong>Background: </strong>Anemia is reported in one-third of the patients with chronic obstructive pulmonary disease (COPD). Anemia, by decreasing oxygen content, can be a contributing factor for hypoxemia. We determined to find whether anemia causes more prominent hypoxia by decreasing the total oxygen content after exercise in anemic patients with COPD.</p><p><strong>Methods: </strong>Stable moderate-to-severe COPD patients with and without anemia were recruited. Arterial blood gas analyses were performed on room air before and after a 6-minute walking test (6MWT). Walking distance, oxygen saturation, and heart rate were recorded in each case before and after the 6MWT. Pulmonary function test measurements and other data were obtained from the chart. The mean and standard deviations were calculated for continuous variables. The independent <i>t</i>-test and Kruskal-Wallis test were performed for numerical covariate and univariate analyses. The paired <i>t</i>-test was used for the analyses of data before and after exercise.</p><p><strong>Results: </strong>A total of 24 male patients were included in the study; 12 of which were anemic. The oxygen content was decreased in the anemic group (15.22 ± 1.28 vs 15.07 ± 1.22) after exercise, but it was not significant. In the non-anemic group, no oxygen content decrease was observed after exercise (18.83 ± 1.41 vs 18.9 ± 1.37). Interestingly, the Spo₂, but not Sao₂, was significantly lower after exercise in anemic patients with COPD (93.46% ± 5.06% vs 88.20% ± 6.35% before and after exercise, respectively).</p><p><strong>Conclusions: </strong>Anemia does not cause more prominent hypoxemia after exercise in patients with COPD. However, the recorded Spo₂ levels were significantly lower after exercise in the anemic patients with COPD.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"12 ","pages":"1179548418796483"},"PeriodicalIF":2.0,"publicationDate":"2018-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548418796483","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36463120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical Left Ventricular Dysfunction is Influenced by Genotype Severity in Patients with Cystic Fibrosis.","authors":"Michael Pallin,&nbsp;Dominic Keating,&nbsp;David M Kaye,&nbsp;Tom Kotsimbos,&nbsp;John W Wilson","doi":"10.1177/1179548418794154","DOIUrl":"https://doi.org/10.1177/1179548418794154","url":null,"abstract":"<p><strong>Background and objective: </strong>Over 2000 genotypes in the cystic fibrosis (CF) gene have been described. These genotypic differences result in variable clinical manifestations of CF, with severity of disease dependent on CF transmembrane conductance (CFTR) protein function. CFTR is widely distributed in nucleated cells, including cardiac myocytes, but the effect of genotype on cardiac function is not known.</p><p><strong>Methods: </strong>This retrospective review of echocardiographic data is from a single adult CF centre between 2000 and 2015. Patients were cohorted based on the functional classification of genotype. 'Severe' patients had both CF genes from functional classification groups 1-3; 'mild' patients had one or no gene from these groups, or in the event of the second gene being unknown were pancreatic sufficient.</p><p><strong>Results: </strong>Genotype and echocardiography were recorded during the inclusion period in 100 patients, 79 of whom were classified as having severe genotypes. Although the severe group were younger they had a lower fractional shortening (33.66 ± 6.6 vs 36.9 ± 6.3, <i>P</i> < .05), left atrial area (14.9 ± 3.6 versus 18.0 ± 4.2 cm²; <i>P</i> < .01) and volume (39.9 ± 18.7 versus 51.0 ± 18.7 mL; <i>P</i> < .05) and showed a trend to lower left ventricular ejection fraction.</p><p><strong>Conclusions: </strong>This study is the first to show that in CF, severity of genotype (functional classification) is associated with cardiac impairment. Patients with severe CF genotype and cardiac dysfunction should be identified to evaluate cardiac response to gene-modifying treatments prior to consideration for lung transplantation.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"12 ","pages":"1179548418794154"},"PeriodicalIF":2.0,"publicationDate":"2018-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179548418794154","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36431408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}